| Literature DB >> 32322712 |
N I Mongalo1, S S Mashele2, T J Makhafola2.
Abstract
Ziziphus mucronata is an important multi-purpose plant species that has been used in African traditional medicine for ages in the treatment of various devastating human and animal infections. The current paper is aimed at providing an overview of uses, toxicology, pharmacological properties and phytochemistry of Z. mucronata. The information used in the current work was retrieved using various search engines, including Pubmed, Science Direct, Google Scholar, Scielo, SciFinder and Scopus. The key words used included Ziziphus mucronata, secondary metabolites, chemistry, biological activity and pharmacology, anti-inflammatory, antimicrobial, antifungal, antiviral, ethnobotanical survey, medicinal uses, safety, toxicology and other related words. Out of the 46 infections which the plant species is used to treat, the most common uses includes sexually transmitted infections, skin infections, diarrhoea and dysentery, respiratory and chest complaints and gynaecological complaints (citations ≥6). Pharmacologically, the plant species exhibited a potential antimicrobial activity yielding a minimum inhibitory concentration of <1 mg/ml against important pathogens which includes Mycobacterium tuberculosis, Moraxella catarrhalis, Staphylococcus aureus, Escherichia coli, Propionibacterium acnes, Candida albicans, Cryptoccoos neoformans amongst other microorganisms. Furthermore, the extracts and compounds from Z mucronata revealed potent antiviral, antioxidant, anti-inflammatory and other activities in vitro. Phytochemically, cyclo-peptide alkaloids (commonly called mucronines) dominates and in conjunction with triterpenes, flavonoids, phenolic acids and anthocyanins. Besides these compounds, the plant species exhibited the presence of important in minerals. These phytoconstituents may well explain the reported biological activities. Although the extracts revealed no cytotoxic effect to Vero cells, further toxicological characteristics of the plant species still needs to be explored. There is also a need to carry out the comprehensive safety profiles of the plant species, including heavy metal detection. Although the plant species revealed important biological activities, which includes antimicrobial, antiviral, anti-diabetic, anti-inflammatory, anti-oxidant, anti-plasmodial, anthelmintic, and anti-anaemic activity in vitro, further research is needed to explore the in vivo studies, other compounds responsible for such activities and the mechanisms of action thereof. Such activities validates the use of the plant species in traditional medicine. The data on the possible use of the plant species in the treatment of diarrhoea, sexually transmitted infections, skin related and gynaecological complaints are scant and still needs to be explored and validated both in vitro and in vivo. Furthermore, the anticancer and anthelmintic activity of the plant species also needs to be explored.Entities:
Keywords: Agricultural science; Anthelmintic; Antidiabetic.; Antimicrobial; Antioxidant; Antiplasmodial; Biological sciences; Chemistry; Cyclopeptides; Ethnomedicinal uses; Food science; Toxicity; Toxicology; Veterinary medicine; Ziziphus mucronate
Year: 2020 PMID: 32322712 PMCID: PMC7170964 DOI: 10.1016/j.heliyon.2020.e03708
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Figure 1Different plant parts of Ziziphus mucronata (stem bark, 1A), (Leaves, thorns, green and ripe fruits, 1B &1C), (Leaves and flower, 1D). (Photos taken by Ofentse Mongalo).
Figure 2Number of citations vs the variety of infections that Z. mucronata may be used to treat.
Indigenous medicinal uses of Ziziphus mucronata.
| Country | Plant part used | Medicinal uses | Reference(s) |
|---|---|---|---|
| South Africa | Roots | Menorrhagia, infertility if women, tooth ache, scrofula, sexually transmitted infections including gonorrhoea and chlamydia. Roots are also used to treat diarrhoea, snake bites, body pains, chest problems and dysentery in humans. | [ |
| Stem barks | Fever, dysentery, rheumatism, respiratory and chest ailments including cough, snake bites, body pains and tuberculosis. | [ | |
| Stem barks | Ethno-veterinary purposes, ring worm. | [ | |
| Roots | Ethno-veterinary purposes. | [ | |
| Leaves | Tuberculosis and diarrhoea in humans. | [ | |
| Whole plant | Sores, boils, swelling and diabetes | [ | |
| Botswana | Stem bark | Tooth ache | [ |
| Zimbabwe | Roots | Abdominal pains, infertility in women, bilharzia, cholera, bladder infections and wounds. | [ |
| Mozambique | Roots | Stomach-ache, muscular pains and constipation | [ |
| Leaves | Abdominal pains, infertility in women and wounds. | [ | |
| Tanzania | Roots | Tonic, colds, lumbago, tumours, foetus disposition, aphrodisiac, stomach-ache, chest pains and hypertension. | [ |
| Kenya | Stem bark | Abdominal pains, diarrhoea, common colds and cough. | [ |
| Roots | Boils, skin infections and pulmonary related infections. | [ | |
| Bukina Faso | Fruits | Relieves pain and inflammation. | [ |
| Roots | Tooth ache and other oral infections. | [ | |
| Mali | Roots | Urinary tract infections, psychological problems and intestinal infections | [ |
| Zambia | Stem barks | Treatment of sexually transmitted infections (STIs) including syphilis, gonorrhoea and chlamydia. | [ |
| Leaves | Ulcers and gonorrhoea. | [ | |
| Roots | Management of HIV-AIDS related infections including pneumonia and STIs such as syphilis, gonorrhoea and chlamydia | [ | |
| Whole plant | Arthritis, chest pains, digestive disorders, weakness, liver complaints, obesity, urinary troubles, diabetes, skin infections, loss of appetite, fever, pharyngitis, bronchitis, anaemia, diarrhoea and insomnia | [ | |
| Nigeria | Leaves | Depression. | [ |
| Whole plant | Mellitus diabetes | [ | |
| Namibia | Whole plant | Gonorrhoea, skin allergy, rush and sore fingers. | [ |
| Roots | Ethno-veterinary purposes. Roots are also used to treat diarrhoea with some stools in the blood, tuberculosis, vomiting and stomach ulcers. | [ | |
| Angola | Roots | Urogenital infections, sore throat, mouth ulcers and diarrhoea. | [ |
| Benin | Roots | Oedema | [ |
| Senegal | Whole plant | Sexually related infections in humans, diabetes, dysentery and leprosy. | [ |
Classes of compounds isolated from Ziziphus mucronata.
| Classes | Plant part | Compounds | Reference(s) |
|---|---|---|---|
| Phenolic acids | Stem bark | Pyrogallol, gallic acid, caffeic acid, | [ |
| Flavonoids | Stem bark | procatechin, catechin, epicatechin, rutin, and taxifolin | [ |
| Peptide alkaloids | Whole roots and root barks | Mucronine A, Mucronine B, Mucronine C, Mucronine D, Mucronine E, Mucronine F, Mucronine G and Mucronine J. | [ |
| Root bark | Abyssenine A, Abyssenine B, Abyssenine C. | [ | |
| Triterpenes | Zizyberanalinic acid | [ | |
| Important Minerals | Seeds | Zinc, potassium, iron, Magnesium, calciumsodium and phosphorus. | [ |
Pharmacological activity of extracts, fractions and isolated compounds from Ziziphus mucronata.
| Activity investigated | Tested plant material | Model used | Tested doses | Control(s) used | Activity and notable results | Experimental evidence | References used |
|---|---|---|---|---|---|---|---|
| Antibacterial activity | Micro-dilution assay | 50 mg/ml diluted | None reported | The petroleum ether extract of the stem bark revealed MIC value of 0.4 mg/ml against | Positive evidence, dose dependence. | [ | |
| Micro-dilution assay | 100 mg/ml serially diluted | Positive control: Neomycin | Methanol extract of the leaf revealed a lowest MIC value of 0.2 mg/ml against | Positive evidence, dose dependence. | [ | ||
| Micro-dilution assay | 32 mg/ml serially diluted | Positive control: Ciprofloxacin | The 1:1 (methanol: dichloromethane) extract revealed a MIC values of 0.01 mg/ml against | Positive evidence, dose dependence. | [ | ||
| Micro-dilution assay | 10 mg/ml diluted | Positive control: None reported | Hexane and chloroform extracts revealed MIC values of 0.21 and 0.27 mg/ml against | Positive evidence, dose dependence. | [ | ||
| Micro-dilution assay | 10 mg/ml diluted | Positive control: Ampicillin | The extract revealed a MIC value of 0.53 mg/ml against both | Positive evidence, dose dependence. | [ | ||
| Micro-dilution assay | 20 mg/ml serially diluted | Positive control: Neomycin | The 90 % methanol extract revealed MIC value of 1.25 mg/ml against | Positive evidence, dose dependence. | [ | ||
| Agar well diffusion assay | 20 mg/ml | Positive control: Neomycin | Acetone and methanol extracts of the leaves revealed a positive inhibition against | Positive evidence. | [ | ||
| Agar well diffusion and Micro-dilution assays | 10 mg/ml | Positive controls: Ampicillin, amoxicillin, tetramycin and gentamycin. | The methanol extract from both leaves and roots revealed a zone of inhibition of 3.25 and 5.0 mm against | Positive evidence, dose dependence. | [ | ||
| Disc diffusion assay and Micro-dilution method. | 10 mg/ml | Positive control: Amoxyllin, tetramycin and gentamycin. | Aqueous extract of the root exhibited zone of inhibition of 5.0 mm against | Positive evidence, dose dependence. | [ | ||
| Micro-dilution method. | A concentration of 64 mg/ml serially diluted. | Positive control: Ciprofloxacin. | Aqueous extract from the stem bark revealed a MIC of 1.0 mg/ml against both | Positive evidence, dose dependence. | [ | ||
| Disc diffusion and Time-log kill methods. | Concentrations ranging from 200 to 1000 μg/ml. | Positive control: None reported. | The extract did not inhibit the growth of both | Inconclusive evidence, not dose dependent. | [ | ||
| Micro-dilution method. | A concentration of 32 mg/ml serially diluted. | Positive control: Ciprofloxacin. | Organic extracts from the leaves revealed a MIC value of 1.0 mg/ml against three bacterial strains such as | Positive evidence, dose dependence. | [ | ||
| Disc Diffusion method. | A concentration of 2.5 mg/disc. | Positive control: Erythromycin | No activity observed | Negative evidence, not dose dependent | [ | ||
| Disc diffusion method | A concentration of 100 mg residue/ml. | Positive control: Neomycin. | Methanol extract of the leaves at 1 mg/ml revealed antibacterial activity of 0.30 relative control drug at 200-500 μg/ml. | Positive evidence, Not dose dependent. | [ | ||
| Micro-dilution method. | Maximum concentration of 4 mg/ml serially diluted. | Positive control: Gentamycin sulphate, vancomycin hydrochloride, penicillin g, imipinem, ampicillin and chloramphenicol. | The extract did not reveal any inhibition at highest concentration tested against clinical strains of | Inconclusive evidence, not dose dependence | [ | ||
| Micro-dilution method. | A concentration of 64 mg/ml serially diluted. | Positive control: Coprofloxacin. | The leaves revealed a MIC value of 0.5 mg/ml against | Positive evidence, dose dependence | [ | ||
| Micro-dilution method. | A concentration of 50 mg/ml serially diluted. | Positive control: Coprofloxacin. | Aqueous extract revealed a MIC value of 0.19 against | Positive evidence, dose dependence | [ | ||
| Micro-dilution method. | A concentration of 50 mg/ml serially diluted. | Positive control: Gentamycin and streptomycin. | The dichloromethane extract revealed a MIC value of 0.08 and 0.13 mg/ml against methicillin resistant | Positive evidence, dose dependence | [ | ||
| Anti-mycobacterial activity | Micro-dilution method. | 10 mg/ml serially diluted | Positive control: Rifampicin and isoniazid | The extract revealed a MIC value of 0.156 mg/ml against | Positive evidence, dose dependence. | [ | |
| Micro-dilution method. | A highest concentration of 100 μg/ml serially diluted. | Positive control: Rifampicin, ethambutol, streptomycin and isoniazid | Acetone extract from stem bark exhibited MIC value of 50 μg/ml against two different | Positive evidence, dose dependence. | [ | ||
| Micro-dilution method. | A concentration of 50 mg/ml serially diluted. | Positive control: Gentamycin and streptomycin. | Dichloromethane extract exhibited a MIC value of <0.156 mg/ml against | Positive evidence, dose dependence | [ | ||
| Micro-dilution method. | A highest concentration of 500 μg/ml. | Positive control: Rifampicin and ethambutol dihydrochloride. | The extract revealed MIC value of >500 μg/ml against pathogenic | Inconclusive evidence, dose dependence. | [ | ||
| Antifungal activity | Micro-dilution method. | A concentration of 64 mg/ml serially diluted. | Positive control: Amphotericin B. | The aqueous extract of the stem revealed a MIC value of 2.0 mg/ml against | Positive evidence, dose dependence. | [ | |
| Disc diffusion assay and Micro-dilution method. | 10 mg/ml | Positive control: Amphotericin B. | The aqueous extract of roots exhibited zone of inhibition of 2.75 and 3.75 mm against | Positive evidence. | [ | ||
| Agar diffusion | 1 g extract diluted with media | Positive control: Ketoconazole | The extract revealed a zone of inhibition of 14.45 mm against | Positive evidence. | [ | ||
| Agar diffusion assay | Not specified | Positive control: Nystatin and Flucytosine. | The extract revealed zone of inhibition of 15 mm against | Positive evidence. | [ | ||
| Cup Plate method | 100 mg/ml diluted 1:10, 1:100 and 1:500. | Negative control: Plates containing PDA. | Boiled aqueous extract revealed a stronger inhibition of 30 to 40 mm against | Positive evidence. | [ | ||
| Agar diffusion assay | 2.5 to 20 % diluted with water | Positive control: 20 % fluconazole. | A 20 % hexane extract exhibited a zone of inhibition of 6.0 and 7.5 mm against | Positive evidence. | [ | ||
| Micro-dilution method. | A concentration of 50 mg/ml serially diluted. | Positive control: Gentamycin and streptomycin. | Hexane extract revealed a MIC value of 1.25 mg/ml against | Positive evidence, dose dependence | [ | ||
| Micro-dilution assay | 32 mg.ml serially diluted. | Positive control: Amphotericin B. | The organic extract revealed a MIC value of 0.1 mg/ml against both | Positive evidence, dose dependence. | [ | ||
| Micro-dilution method. | A concentration of 32 mg/ml serially diluted. | Positive control: Amphotericin B. | Organic extract from the leaves revealed a MIC value of 1.0 mg/ml against | Positive evidence, dose dependence. | [ | ||
| Micro-dilution method. | A concentration of 64 mg/ml serially diluted. | Positive control: Amphotericin B. | The organic leaf extract revealed a MIC value of 2.0 mg/ml against | Positive evidence, dose dependence. | [ | ||
| Micro-dilution method. | A concentration of 64 mg/ml serially diluted. | Positive control: Amphotericin B. | The leaves extract revealed a MIC value of 1.0 and 4.0 mg/ml against | Positive evidence, dose dependence | [ | ||
| Direct contact of extract and spores in a test tube. | Fractions were tested at 1mg.ml | Positive control: Catechin and rutin. | Fractions FZ2 and FZ3 revealed a 57.14 % inhibition of spores from | Positive evidence. | [ | ||
| Anti-viral activity | DNA polymerase and RNase H activities of HIV-1 RT. | 400 μg/ml serially diluted. | Positive control: DNA aptamer (ODN 93) | The methanol and aqueous extracts revealed LC50 values of 75 and 81.5 μg/ml against RNase H and RDDP respectively. | Positive evidence, dose dependence. | [ | |
| Reverse transcriptase assay. | Two concentrations of 50 and 100 μg/ml | Positive control: | Both concentrations revealed less than 20 % inhibition of enzyme. | Inconclusive evidence, Not dose dependent | [ | ||
| Antioxidant activity | ABTS and DPPH assays. | Concentrations ranging from 0.007 to 1.25 mg/ml. | Positive control: Trolox. | The methanol extract exhibited IC50 value of 19 and 29 μg/ml against ABTS and DPPH respectively. | Positive evidence, dose dependence. | [ | |
| DPPH, Hydroxyl radical and Nitric oxide radical assays. | Concentrations ranging from 15 to 240 | Positive control: Trolox, gallic acid and ascorbic acid. | Ethanol extract from the leaves, roots and stem bark exhibited IC50 values of 1.68; 1.38 and 1.99 μg/ml against DPPH free radical. | Positive evidence, dose dependence. | [ | ||
| DPPH, ABTS and FRAP. | Concentrations ranging from 0.02 to 0.1 mg/ml. | Positive control: BHT, rutin and ascorbic acid. | Ethanol and acetone extracts revealed potent IC50 values of 31 and 32 μg/ml against ABTS free radical, while BHT exhibited 34 μg/ml. | Positive evidence, dose dependence. | [ | ||
| DPPH assay. | 100 to 600 μg/ml. | Positive control: BHT. | The methanol extract revealed IC50 value of 45.19 μg/ml against DPPH. | Positive evidence, dose dependence. | [ | ||
| DPPH and ABTS assays. | Concentrations ranging from 2.5 to 100 μg/ml. | Positive control: Gallic acid and ascorbic acid. | The methanol extract revealed IC50 value of 7.21 μg/ml against ABTS free radical. | Positive evidence, dose dependence. | [ | ||
| DPPH and ABTS assays. | Concentrations ranging from 0.1 to 300 μg/ml. | Positive control: | The methanol and aqueous extracts revealed IC50 values of 11.18 and 20.78 μg/ml against ABTS respectively, while methanol extract revealed 89.81 μg/ml against DPPH. | Positive evidence, dose dependence. | [ | ||
| DPPH, β-Carotene assays. | Concentrations of 100 and 200 μg/ml serially diluted in DPPH and β-Carotene assay respectively. | Positive control: BHT and ascorbic acid. | The aqueous extract of the 16 years old stored plant material revealed an IC50 value of 18.1 μg/ml against DPPH. | Positive evidence, dose dependence. | [ | ||
| DPPH and metal chelating activity. | Concentration of 100 μg/ml serially diluted. | Positive control: Trolox, EDTA and ascorbic acid. | Acetone extract of the stem bark revealed IC50 value of 15.27 and 55.67 μg/ml against DPPH and Metal chelation activity respectively. | Positive evidence, dose dependence. | [ | ||
| Anti-inflammatory and anti-neurodegenerative effect | Ache assay, micro plate | Concentrations ranging from 0.007 to 0.16 mg/ml. | Positive control: Galantamine. | The ethyl acetate extract revealed IC50 value of 1 μg/ml. | Positive evidence, dose dependence. | [ | |
| COX-1 and COX-2 assays. | A single concentration of 250 μg/ml. | Positive control: Indomethacin. | The 90 % methanol extract revealed 66.5 and 66.2 % against COX-1 and COX-2 respectively. | Positive evidence, Not dose dependent. | [ | ||
| Cyclooxygenase assay. | A single concentration of 20 mg residue/ml. | Positive control: Indomethacin. | Ethanol extract of the leaves revealed 87 % inhibition of cyclooxygenase. | Positive evidence, Not dose dependent. | [ | ||
| Two concentrations of 50 and 100 μg/ml | Positive control: Aminoguanidine. | The extracts did not inhibit nitric oxide production and induce the activation of macrophages. | Positive evidence. | [ | |||
| Anti-diabetic activity | Direct ingestion, | Two concentrations, 150 ad 300 mg/kg. | Positive control: None reported | At 300 mg/kg, the fraction revealed a clear reduction in blood glucose, improved glucose tolerance ability and higher serum insulin. | Positive evidence. Not dose dependent. | [ | |
| Three concentrations of 15.6, 31.2 and 62.5 μg/ml were investigated | Positive control: Acarbose. | All the extracts revealed IC50 values > 62.5 μg/ml in both α-amylase and α-glucosidase. Further, the extracts resulted in higher glucose uptake in C2C12 cells only. | Positive evidence, dose dependence | [ | |||
| Four concentrations of 30, 60, 90, 120 and 240 μg/ml. | Positive control: Acarbose. | Butanol, aqueous, ethyl acetate and dichloromethane fractions revealed IC50 values of 1.41, 4.38, 23.6 and 43.91 μg/ml against α-glucosidase while control revealed 55.59 μg/ml. | Positive evidence, dose dependence | [ | |||
| Histopathologic and hepatoprotective effect | Dimethoate induced liver | 100, 200 and 300 mg/kg extracts. | Negative Control: Rats fed with dimethoate and water instead of extract. | The extract resulted in a significant decline serum marker enzymes SGOT, SGPT and ALP. The extract further resulted in less necrosis, limited loss of cell boundaries and reduced loss of intact hepatocytes. | Positive evidence, dose dependence | [ | |
| Direct ingestion, | Two concentrations, 150 ad 300 mg/kg. | Negative Control: Rats fed with water instead of extract. | The fraction resulted in less or no effect on the renal and hepatic damage caused by streptomycin induced diabetes. | Positive evidence, Not dose dependent. | [ | ||
| Anthelmintic activity | Direct contact. | A single dose of 1 mg/ml. | Positive control: Levamisole. | Organic extract from twigs revealed average % worm death of 69.47 against | Positive evidence. Not dose dependent. | [ | |
| Larval mortality and egg hatch inhibition assays. | Concentration ranging from 0.06 to 4 mg/ml. | Positive control: Albendazole. | Methanol extract revealed LC50 value of 3.9 and 2.65 mg/ml against | Positive evidence, Dose dependence. | [ | ||
| Direct contact | A concentration of 200 mg/ml diluted. | Positive control: None reported. | The root bark extract revealed an effect on cestodes of | Positive evidence, Dose dependence. | [ | ||
| Anti-plasmodial activity | Flow cytometry assay. | Concentration of 100 mg/ml serially diluted. | Positive control: Chloroquine. | Acetone extract revealed LC50 value of 4.13 μg/ml against | Positive evidence, Dose dependence. | [ | |
| Concentration of 100 mg/ml serially diluted. | Positive control: Qiunine and chloroquine. | The acetone extract of fruit revealed LC50 value of 67.18 μg/ml | Positive evidence, Dose dependence. | [ | |||
| A concentration of 100 μg/ml, serially diluted. | Positive control: None used. | Both aqueous and methanol extracts revealed LC50 values >20 μg/ml against | Positive evidence, Dose dependence. | [ | |||
| pLDH assay | Concentrations ranging from 0.2 to 100 μg/ml. | Positive control: Chloroquine diphosphate | The extract revealed LC50 value of 12.0 μg/ml against chloroquine sensitive strain D10 of | Positive evidence, Dose dependence | [ | ||
| A concentration of 100 μg/ml, serially diluted. | Positive control: Chloroquine phosphate and artemisinin. | Aqueous extract of the leaves revealed anti-plasmodial activity of >100 μg/ml against | Positive evidence, dose dependence. | [ | |||
| pLDH assay for growth of | Concentrations ranging from 0 to 50 μg/ml. | Positive control: Chloroquine for | Fractions and extract revealed potent inhibition of both | Positive evidence, dose dependence. | [ | ||
| Anti-sickling effect (Anti-anaemic effect) | Emmel test, | Different concentrations of 20 to 160 μg/ml. | Positive control: None reported. | Ethanol extracts of both stem bark and roots revealed > 70 % anti-sickling effect in the Emmel test. | Positive evidence, Dose dependence. | [ | |
| Anticancer activity | Naphthol blue black assay | Two concentrations of 10 and 100 μg/ml. | Negative control: Cells and DMSO. | The extract revealed 50 to 75 % inhibition of HeLa, HT29 and A431 cells at 100 μg/ml. | Positive evidence, Not dose dependent. | [ | |
| MTT assay and APOPercantage TM assay against HeLa, Caco-2, Chinese harmster ovary cells, KMST-6, H157 and H4 cells. | 0 to 1000 μg/ml. | Negative control: Cells only without extract. | Dichloromethane extract revealed LC50 value of 126.73 μg/ml against H4 cell line. Dichloromethane, methanol and ethanol extracts revealed selective inhibition of Caco-2. | Positive evidence, Dose dependence. | [ | ||
| Mutagenicty/Genotoxicity | Ames test. | 50, 500 and 5000 μg/ml concentrations of plant extracts. | Positive control: 4-Nitoquinoline-N-oxide (4NQO) | The extracts were found to be mutagenic against strain TA98. | Positive evidence, Dose dependence. | [ | |
| VITOTOX test, Ames test in TA98 and TA100 strains with and without metabolic activation. | 0.05, 0.5 and 5.0 mg/ml plant extracts. | The positive controls used: 4- Nitroquinoline 1-oxide (4-NQO) (for TA98 and TA100 without S9) and benzo[a] pyrene (B-[a]-P) (for TA98 and TA100 with S9). | The 90% methanol extract showed a mutagenic effect for TA98 in the presence of S9 mix alone. | Positive evidence, Dose dependence. | [ | ||
| VITOTOX test Ames test in TA98 and TA100 strains with and without metabolic activation. | 0.05, 0.5 and 5.0 mg/ml plant extracts | The positive controls used: 4- Nitroquinoline 1-oxide (4-NQO) (for TA98 and TA100 without S9) and benzo[a] pyrene (B-[a]-P) (for TA98 and TA100 with S9). | The 90% methanol extracts showed a mutagenic effect in strain TA98. | Positive evidence, Dose dependence. | [ | ||
| Ames, Umu-C and VITOTOX® tests, and with the micronucleus test and alkaline comet assay in human white blood cells in the absence of S9 only. | 0.05, 0.5 and 5.0 mg/ml plant extracts | The positive controls used: 4- Nitroquinoline 1-oxide (4-NQO) (for TA98 and TA100 without S9) and benzo[a] pyrene (B-[a]-P) (for TA98 and TA100 with S9). | The extracts did not reveal any mutagenicity. | Positive evidence, Dose dependence. | [ | ||
| Ames test in TA98, TA100 and TA1535 strains in the absence of metabolic activation. | 0.05, 0.5 and 5.0 mg/ml plant extracts. | The positive controls used: 4- Nitroquinoline 1-oxide | The plant extracts of both fresh and long-term stored materials did not show any mutagenic effect against the three tester bacterial strains. | Positive evidence, Dose dependence. | [ |